Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active driver of IBD pathogenesis, making the IL-23/Th-17 inflammatory signaling axis a promising therapeutic target. Monoclonal antibodies (mAbs) have rapidly emerged at the forefront of anti-IL-23 targeted therapies, with structural differences between agents yielding unique clinical profiles that impact the durability of patient outcomes. In collaboration with a multidisciplinary care team, clinicians must understand how to tailor decision-making to the evolving science of cytokine-targeting therapies and the individual needs of patients with IBD. In this CME Outfitters recorded symposium, expert faculty will instruct learners on the role of pro-inflammatory cytokines in the pathogenesis of IBD. Learners will be guided on the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis and how to appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD. Faculty will model the development of individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-02-28 06:00:00
- End Date: 2025-02-28 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology, Internal Medicine